window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 23, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Fragile X syndrome

  • Central Nervous System,Clinical Development,Clinical Trials,Neurosciences,Partnerships & Funding,Rare Diseases

    Servier acquires Kaerus drug candidate for Fragile X syndrome, the most common genetic cause of autism

    Servier has acquired KER-0193 from Kaerus Bioscience, gaining a potential [...]

    September 16, 2025
  • Clinical Trials,Drug Development

    Kaerus receives dual FDA designations for lead Fragile X candidate

    Kaerus Bioscience has been granted Orphan Drug Designation and Rare [...]

    May 19, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Emalex wins US patent for ecopipam ODT as Tourette access program grows
    Categories: Clinical Development, Drug Development, FDA, Neurosciences, Pharmaceuticals and therapeutics, Rare Diseases
  • FairJourney Bio opens cryo-EM facility in San Diego for antibody discovery
    Categories: Biotech, Drug discovery, Facilities and infrastructure, Research & Development, Technology and platforms
  • Kinesin-2 motor variants shown to control cargo transport in neurons
    Categories: Neurosciences, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top